Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis

Pyrotinib-containing regimens demonstrate tumor response, disease control, and survival with manageable toxicity in any line of treatment for HER2-positive metastatic breast cancer, according to data from a systematic review and meta-analysis of prospective and retrospective trials. Overall objective response rate was 0.49 (95% CI: 0.40-0.58) and 0.52 (95% CI: 0.32-0.71) in a subgroup of patients with brain metastases, and combined median PFSs were 8.2 months (95% CI: 6.8-9.5) and 8.9 months (95% CI: 6.2-11.7) for the brain metastases group.